China approves another inactivated Covid vax for emergency use
By IANS |
3 Views
beijing : China s Anti-Corona Vaccine Helps International Fight Against Epidemic. Image Source: IANS News
Beijing, May 15 : China has approved one more inactivated Covid-19 vaccine for emergency use, according to an announcement by the developer of the jab.
Shenzhen Kangtai Biological Products Co., Ltd., the developer, said on Friday that the vaccine it developed has started related work for Phase III clinical trial, reports Xinhua news agency.
The vaccine reported no adverse events with an intensity of grade 3 or above in the first two phases of its clinical trials, according to the company s research submitted to MedRxiv, a web portal distributing preprints about health sciences.
news
Private Company Says MOH Has Approved Its Phase 3 Clinical Trial Of COVID-19 Vaccine
The company, which deals in tourism and property, stated that this will help Malaysia attract huge investment as well as create job opportunities in the pharmaceutical sector.
By Sadho Ram â 28 Apr 2021, 06:07 PM
Subscribe to our Telegram channel for our latest stories and breaking news.
A property developer has obtained the Ministry of Health s approval for its Phase 3 clinical trial study of inactivated COVID-19 trial vaccines in Malaysia, as per its announcement on Bursa Malaysia
With the approval, the property developer Yong Tai Berhad â under its healthcare subsidiary YTB Healthcare Sdn Bhd (YTBH) â has become the first private company to initiate and sponsor the Phase 3 clinical trial of the COVID-19 vaccines in Malaysia.
KUALA LUMPUR (April 26): Property developer Yong Tai Bhd said its healthcare subsidiary has obtained approval from the Ministry of Health s Medical Review & Ethics Committee (MREC) for its Phase III clinical trial study of inactivated Covid-19 trial vaccines in Malaysia. The board wishes to announce that MREC had vide its letter dated April 23, approved the said Phase III Clinical Trial study to be carried out in Malaysia involving 3,000 subjects, the group said in a bourse filing today.
The health ministry has not made a statement on this matter so far.
Yong Tai said its unit, YTB Healthcare Sdn Bhds (YTBH), has formalised the Phase III clinical trial with its partner, Shenzhen Kangtai Biological Products Co Ltd (SZKT), since December last year. SZKT is a vaccine manufacturer in China.
M sia, China working together in procurement deals, clinical trials for other Chinese vaccines, says China envoy thestar.com.my - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thestar.com.my Daily Mail and Mail on Sunday newspapers.
Global Pneumonia Vaccine Market 2021 Global Trend, Segmentation and Opportunities Forecast To 2025 The forecast involves key details on market size, market share, statistics, application, and revenue.
BriefingWire.com, 2/20/2021 - Facto Market Insights recently published market research study on the Global Pneumonia Vaccine Market (2021-2025) to its own collection of research reports. The study report covers detailed analysis of market sizing and forecasting of the market covering the market drivers, challenges, opportunity analysis, and tendencies, together with assorted important insights in the worldwide industry. The study report also contains the investigation of regional producers and brand new market players, covering all of the information acceptable for its customers to produce strategic business decisions in the business.